- Zacks
Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
- Zacks
Merck's (MRK) Co-formulation Therapy Fails Lung Cancer Study
Data from a mid-stage study showed that Merck's (MRK) MK-7684A did not improve progression-free survival as a potential treatment for patients with metastatic non-small cell lung cancer.
- Benzinga
Merck's Keytruda Combo Therapy Less Effective Than Chemo In Lung Cancer Patients, Data Shows
https://cdn.benzinga.com/files/images/story/2023/03/17/mrk.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Merck & Co Inc's (NYSE: MRK) MK-7684A failed the open-label portion of a Phase 2 study KeyVibe-002 trial. MK-7684A, a combination of Keytruda (pembrolizumab) and in-house anti-TIGIT compound vibostolimab, did not improve patients' progression-free survival compared to chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) with progressive disease after treatment wit
